logo-loader
viewOncimmune

Oncimmune inks collaboration with Genentech that broadens the "commercial footprint” of its ImmunoINSIGHTS service business

"Genentech is a pre-eminent biotechnology company, considered a leader in the biotech industry today,” said chief executive, Dr Adam Hill

Oncimmune -

Oncimmune Holdings PLC (AIM:ONC) said it has signed a collaboration to profile samples from Genentech's rheumatology clinical trials, broadening the "commercial footprint” of its ImmunoINSIGHTS service business.

Oncimmune’s NavigAID arrays will be used to characterise the auto-antibody profiles of patients taking part in studies for rheumatological diseases, including the autoimmune disease lupus.

Following the project’s completion, Genentech, which is now part of Swiss giant Roche, has the option to expand the contract to profile additional samples.

"Genentech is a pre-eminent biotechnology company, considered a leader in the biotech industry today,” Oncimmune chief executive, Dr Adam Hil said in a statement.

“This contract adds to the already substantial pipeline of contracted revenue through our ImmunoINSIGHTS business in the full-year 2021 and provides another opportunity to show how our NavigAID technology can assist partners in increasing their ability to better assess where their medicines could make an impact,” he added.

Quick facts: Oncimmune

Price: 177.5 GBX

AIM:ONC
Market: AIM
Market Cap: £112.79 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Oncimmune CEO says they're seeing 'significant interest' in its EarlyCDT...

Oncimmune Holdings PLC's (LON:ONC) Adam Hill tells Proactive the next 18 months are expected to create substantial revenues within the EarlyCDT lung cancer test business while the pipeline of contracts within the ImmunoINSIGHTS services business is building. In a trading update covering the...

on 5/6/20

2 min read